Wild-type and mutated IDH1/2 enzymes and therapy responses

Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of d-2-hydroxyglutarate. In various...

Descripción completa

Detalles Bibliográficos
Autores principales: Molenaar, Remco J., Maciejewski, Jaroslaw P., Wilmink, Johanna W., van Noorden, Cornelis J. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895605/
https://www.ncbi.nlm.nih.gov/pubmed/29367755
http://dx.doi.org/10.1038/s41388-017-0077-z
_version_ 1783313678997651456
author Molenaar, Remco J.
Maciejewski, Jaroslaw P.
Wilmink, Johanna W.
van Noorden, Cornelis J. F.
author_facet Molenaar, Remco J.
Maciejewski, Jaroslaw P.
Wilmink, Johanna W.
van Noorden, Cornelis J. F.
author_sort Molenaar, Remco J.
collection PubMed
description Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of d-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.
format Online
Article
Text
id pubmed-5895605
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-58956052018-04-13 Wild-type and mutated IDH1/2 enzymes and therapy responses Molenaar, Remco J. Maciejewski, Jaroslaw P. Wilmink, Johanna W. van Noorden, Cornelis J. F. Oncogene Review Article Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of d-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed. Nature Publishing Group UK 2018-01-25 2018 /pmc/articles/PMC5895605/ /pubmed/29367755 http://dx.doi.org/10.1038/s41388-017-0077-z Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. If you remix, transform, or build upon this article or a part thereof, you must distribute your contributions under the same license as the original. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/.
spellingShingle Review Article
Molenaar, Remco J.
Maciejewski, Jaroslaw P.
Wilmink, Johanna W.
van Noorden, Cornelis J. F.
Wild-type and mutated IDH1/2 enzymes and therapy responses
title Wild-type and mutated IDH1/2 enzymes and therapy responses
title_full Wild-type and mutated IDH1/2 enzymes and therapy responses
title_fullStr Wild-type and mutated IDH1/2 enzymes and therapy responses
title_full_unstemmed Wild-type and mutated IDH1/2 enzymes and therapy responses
title_short Wild-type and mutated IDH1/2 enzymes and therapy responses
title_sort wild-type and mutated idh1/2 enzymes and therapy responses
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895605/
https://www.ncbi.nlm.nih.gov/pubmed/29367755
http://dx.doi.org/10.1038/s41388-017-0077-z
work_keys_str_mv AT molenaarremcoj wildtypeandmutatedidh12enzymesandtherapyresponses
AT maciejewskijaroslawp wildtypeandmutatedidh12enzymesandtherapyresponses
AT wilminkjohannaw wildtypeandmutatedidh12enzymesandtherapyresponses
AT vannoordencornelisjf wildtypeandmutatedidh12enzymesandtherapyresponses

Ejemplares similares